IE56026B1
(en)
*
|
1982-10-19 |
1991-03-27 |
Cetus Corp |
Cysteine-depleted muteins of biologically active proteins
|
US5288852A
(en)
*
|
1984-03-06 |
1994-02-22 |
Dainippon Pharmaceutical Co., Ltd. |
Human tumor necrosis factor polypeptides
|
US6107465A
(en)
*
|
1984-12-21 |
2000-08-22 |
Otsuka Pharmaceutical Co., Ltd. |
IL-1β and derivatives thereof and drugs
|
US5342614A
(en)
*
|
1984-12-21 |
1994-08-30 |
Otsuka Pharmaceutical Co., Ltd. |
Method of treating arthritus or inflammation with IL-1β or derivatives thereof
|
US5516896A
(en)
*
|
1985-02-25 |
1996-05-14 |
Zymogenetics, Inc. |
Biologically active B-chain homodimers
|
US5244806A
(en)
*
|
1985-08-26 |
1993-09-14 |
Eli Lilly And Company |
DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
|
US5859208A
(en)
*
|
1988-07-06 |
1999-01-12 |
Fiddes; John C. |
Human basic fibroblast growth factor analog
|
EP0247906B1
(de)
*
|
1986-02-04 |
1994-12-28 |
Mizuno, Den'Ichi |
Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe
|
US5008374A
(en)
*
|
1986-03-14 |
1991-04-16 |
Otsuka Pharmaceutical Co., Ltd. |
IL-1α derivatives and drugs
|
US5900476A
(en)
*
|
1986-05-30 |
1999-05-04 |
The Scripps Research Institute |
Therapeutic domains of van Willebrand factor
|
EP0257406B2
(de)
*
|
1986-08-06 |
1998-08-12 |
Ajinomoto Co., Inc. |
Rekombinanter B-Zell-Differenzierungsfaktor
|
US5681934A
(en)
*
|
1986-09-30 |
1997-10-28 |
Board Of Regents, The University Of Texas System |
47-kilodalton antigen of Treponema pallidum
|
US6994988B1
(en)
|
1987-02-12 |
2006-02-07 |
Genetech, Inc. |
Methods and deoxyribonucleic acid for the preparation of tissue factor protein
|
US7049131B1
(en)
*
|
1987-02-12 |
2006-05-23 |
Genentech, Inc. |
Methods and deoxyribonucleic acid for the preparation of tissue factor protein
|
US5852177A
(en)
*
|
1987-02-24 |
1998-12-22 |
Takeda Chemical Industries, Ltd. |
Basic fibroblast growth factor (bFGF) muteins
|
AU1346488A
(en)
*
|
1987-02-26 |
1988-09-26 |
Cetus Corporation |
Arginine-depleted human tumor necrosis factor
|
ZA884012B
(en)
*
|
1987-06-04 |
1989-02-22 |
Zymogenetics Inc |
Tissue plasminogen activator analogs having modified growth factor domains
|
DE68929273T2
(de)
*
|
1988-08-24 |
2001-07-05 |
American Cyanamid Co |
Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
|
DE3907244A1
(de)
*
|
1989-03-07 |
1990-09-13 |
Knoll Ag |
Erzeugnisse, enthaltend ein lithiumsalz und einen tumor-nekrose-faktor
|
US5621078A
(en)
*
|
1989-03-22 |
1997-04-15 |
Merck & Co., Inc. |
Modified pseudomonas exotoxin PE40
|
WO1990012877A1
(en)
*
|
1989-04-19 |
1990-11-01 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
US6207798B1
(en)
*
|
1989-08-03 |
2001-03-27 |
Merck & Co., Inc. |
Modified PE40 toxin fusion proteins
|
FR2651130B1
(fr)
*
|
1989-08-23 |
1991-12-13 |
Roussel Uclaf |
Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.
|
AU641949B2
(en)
*
|
1989-10-10 |
1993-10-07 |
Amgen, Inc. |
Compositions and methods for treating or preventing infections in canine and feline animals
|
US7144731B2
(en)
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
GEP20002145B
(en)
*
|
1989-10-16 |
2000-06-25 |
Amgen Inc Us |
Stem Cell Factor
|
US6852313B1
(en)
|
1989-10-16 |
2005-02-08 |
Amgen Inc. |
Method of stimulating growth of melanocyte cells by administering stem cell factor
|
US20040181044A1
(en)
*
|
1989-10-16 |
2004-09-16 |
Zsebo Krisztina M. |
Method of stimulating growth of epithelial cells by administering stem cell factor
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US6566098B1
(en)
*
|
1990-09-14 |
2003-05-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
DNA encoding truncated hepatocyte growth factor variants
|
JPH05255393A
(ja)
*
|
1990-09-21 |
1993-10-05 |
Ishihara Sangyo Kaisha Ltd |
ポリペプチド
|
ATE141093T1
(de)
*
|
1990-09-21 |
1996-08-15 |
Ishihara Sangyo Kaisha |
Polypeptid
|
US5310883A
(en)
*
|
1990-11-23 |
1994-05-10 |
American Cyanamid Company |
Chimeric fibroblast growth factors
|
US6833354B1
(en)
*
|
1990-12-19 |
2004-12-21 |
Kaken Pharmaceutical Co., Ltd. |
Agent for the treatment of bone diseases
|
WO1992017192A1
(en)
*
|
1991-03-27 |
1992-10-15 |
The Scripps Research Institute |
Therapeutic fragments of von willebrand factor
|
JP3303211B2
(ja)
*
|
1991-04-26 |
2002-07-15 |
武田薬品工業株式会社 |
bFGFムテインおよびその製造法
|
US5847086A
(en)
*
|
1991-06-20 |
1998-12-08 |
Centeon L.L.C. |
Therapeutic fragments of von Willebrand factor
|
ES2233924T3
(es)
*
|
1991-06-20 |
2005-06-16 |
Aventis Behring L.L.C. |
Un procedimiento para preparar fragmentos terapeuticos de factor von willebrand.
|
ZA924674B
(en)
*
|
1991-07-02 |
1993-04-28 |
Imclone Systems Inc |
Cysteine depleted il-6 mutein
|
US5248604A
(en)
*
|
1991-07-22 |
1993-09-28 |
Bio-Technology General Corp. |
Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
GB9204439D0
(en)
*
|
1992-02-27 |
1992-04-15 |
Fujisawa Pharmaceutical Co |
A new cephalosporin c acylase
|
US5326695A
(en)
*
|
1992-05-15 |
1994-07-05 |
Ludwig Institute For Cancer Research |
Platelet derived growth factor agonists
|
US5444151A
(en)
*
|
1992-05-15 |
1995-08-22 |
Ludwig Institute For Cancer Research |
Platelet derived growth factor antagonists
|
US5349056A
(en)
*
|
1992-10-09 |
1994-09-20 |
Regeneron Pharmaceuticals |
Modified ciliary neurotrophic factors
|
US5420019A
(en)
*
|
1993-02-02 |
1995-05-30 |
Xoma Corporation |
Stable bactericidal/permeability-increasing protein muteins
|
US7060484B1
(en)
|
1993-11-12 |
2006-06-13 |
Gilead Sciences, Inc. |
Polypeptides and coagulation therapy
|
EP0728210B1
(de)
*
|
1993-11-12 |
2005-04-13 |
Gilead Sciences, Inc. |
Thrombin mutanten
|
US20030220233A1
(en)
|
1994-01-24 |
2003-11-27 |
Neorx Corporation |
Radiolabeled annexins
|
US5968477A
(en)
*
|
1994-01-24 |
1999-10-19 |
Neorx Corporation |
Radiolabeled annexin conjugates with hexose and a chelator
|
US5545723A
(en)
*
|
1994-03-15 |
1996-08-13 |
Biogen Inc. |
Muteins of IFN-β
|
ES2196082T3
(es)
*
|
1994-10-13 |
2003-12-16 |
Amgen Inc |
Analagos del factor de crecimiento de queratinocitos.
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6818220B1
(en)
|
1994-11-14 |
2004-11-16 |
Licentia Ltd. |
Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
|
US6130071A
(en)
*
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
IL114615A0
(en)
|
1995-07-16 |
1995-11-27 |
Yeda Res & Dev |
Modulators of the function of fas receptors and other proteins
|
IL117175A
(en)
*
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
US7727761B2
(en)
*
|
1995-08-01 |
2010-06-01 |
Vegenics Limited |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US20030202980A1
(en)
*
|
1995-12-29 |
2003-10-30 |
Caplan Michael J. |
Methods and reagents for decreasing clinical reaction to allergy
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US6743422B1
(en)
|
1996-10-15 |
2004-06-01 |
Amgen, Inc. |
Keratinocyte growth factor-2 products
|
US20030144202A1
(en)
*
|
1996-10-15 |
2003-07-31 |
Amgen Inc. |
Uses of keratinocyte growth factor-2
|
AU5696198A
(en)
|
1996-12-06 |
1998-06-29 |
Amgen, Inc. |
Combination therapy using a tnf binding protein for treating tnf-mediated diseases
|
EP2003203A1
(de)
*
|
1996-12-23 |
2008-12-17 |
Immunex Corporation |
Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
|
AU735459B2
(en)
|
1997-01-30 |
2001-07-12 |
University Of Virginia Patent Foundation |
Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
|
US7125714B2
(en)
*
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
HU229841B1
(en)
*
|
1997-04-15 |
2014-09-29 |
Daiichi Sankyo Co Ltd |
Antibodies against obm
|
WO1998046751A1
(en)
|
1997-04-16 |
1998-10-22 |
Amgen Inc. |
Osteoprotegerin binding proteins and receptors
|
US6316408B1
(en)
*
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
EP1173191A4
(de)
*
|
1997-05-13 |
2004-12-01 |
Univ California |
Neuartige antiangiogenese peptidagenzien sowie ihre therapeutische und diagnostische verwendung
|
US7723473B2
(en)
*
|
1997-06-19 |
2010-05-25 |
St. Louis University |
Peptide antagonists of TGF-beta family members and therapeutic uses thereof
|
IL136621A0
(en)
|
1997-12-17 |
2001-06-14 |
Immunex Corp |
Cell surface glycoproteins associated with human b cell lymphomas
|
US8101349B2
(en)
|
1997-12-23 |
2012-01-24 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells and their methods of use II
|
US7879977B2
(en)
|
1998-01-31 |
2011-02-01 |
University Of Arkansas |
Methods and reagents for decreasing clinical reaction to allergy
|
DE69940805D1
(de)
|
1998-01-31 |
2009-06-10 |
Sinai School Medicine |
Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
US6447771B1
(en)
*
|
1999-03-19 |
2002-09-10 |
Hyseq, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
AU762392B2
(en)
*
|
1998-07-16 |
2003-06-26 |
Arca Biopharma, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6387645B1
(en)
|
1998-07-16 |
2002-05-14 |
Hyseq, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6476211B1
(en)
|
1998-07-16 |
2002-11-05 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
US6979442B1
(en)
|
1998-08-17 |
2005-12-27 |
Pfizer Inc. |
Stabilized protein compositions
|
JP5329729B2
(ja)
|
1998-09-03 |
2013-10-30 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
脈管形成に有効な単位用量のfgf−2および使用方法
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6696063B1
(en)
*
|
1998-12-30 |
2004-02-24 |
Applied Research Systems Ars Holding N.V. |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US6350447B1
(en)
|
1999-01-29 |
2002-02-26 |
Hyseq, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6783959B1
(en)
|
1999-01-29 |
2004-08-31 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6780977B1
(en)
|
1999-01-29 |
2004-08-24 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6899875B1
(en)
|
1999-01-29 |
2005-05-31 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6335013B1
(en)
|
1999-03-19 |
2002-01-01 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
WO2000061755A2
(en)
*
|
1999-04-09 |
2000-10-19 |
Chiron Corporation |
Secreted human proteins
|
US6514729B1
(en)
|
1999-05-12 |
2003-02-04 |
Xencor, Inc. |
Recombinant interferon-beta muteins
|
US6703221B1
(en)
|
1999-08-19 |
2004-03-09 |
Chiron Corporation |
Notch receptor ligands and uses thereof
|
US6825333B1
(en)
*
|
1999-08-20 |
2004-11-30 |
Chiron Corporation |
EGFH2 genes and gene products
|
AU783208B2
(en)
*
|
1999-12-09 |
2005-10-06 |
Novartis Vaccines And Diagnostics, Inc. |
Method for administering a cytokine to the central nervous system and the lymphatic system
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
CA2403292C
(en)
*
|
2000-04-06 |
2011-02-08 |
Panacea Pharmaceuticals, Llc |
Microbial delivery system
|
US8246945B2
(en)
*
|
2000-04-06 |
2012-08-21 |
University Of Arkansas |
Methods and reagents for decreasing clinical reaction to allergy
|
US20050063994A1
(en)
*
|
2000-04-06 |
2005-03-24 |
Caplan Michael J. |
Methods and reagents for decreasing clinical reaction to allergy
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1276849A4
(de)
*
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
Albumin fusionsproteine
|
CA2407897A1
(en)
*
|
2000-05-05 |
2001-11-15 |
Cytos Biotechnology Ag |
Molecular antigen arrays and vaccines
|
US7700359B2
(en)
*
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
ATE397094T1
(de)
|
2000-06-15 |
2008-06-15 |
Novartis Vaccines & Diagnostic |
Polynukleotide zur bestimmung von kolonkrebs
|
FR2811323B1
(fr)
*
|
2000-07-07 |
2006-10-06 |
Fuma Tech Gmbh |
Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
|
JP2004504021A
(ja)
*
|
2000-07-14 |
2004-02-12 |
カイロン コーポレイション |
テトラスパンタンパク質およびその使用
|
JP2004535765A
(ja)
|
2000-12-07 |
2004-12-02 |
カイロン コーポレイション |
前立腺癌においてアップレギュレートされた内因性レトロウイルス
|
WO2002052047A2
(en)
*
|
2000-12-22 |
2002-07-04 |
Mergen Ltd. |
Methods for identifying g-protein coupled receptors associated with diseases
|
US7094409B2
(en)
|
2001-01-19 |
2006-08-22 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of allergic eosinophilic diseases
|
WO2002059337A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Georgetown University School Of Medicine |
Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002303262A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene shinc-1 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ES2340532T3
(es)
|
2001-06-05 |
2010-06-04 |
Curevac Gmbh |
Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo.
|
AU2002355955A1
(en)
*
|
2001-08-13 |
2003-03-03 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
CA2460546A1
(en)
*
|
2001-09-14 |
2003-03-27 |
Invitrogen Corporation |
Dna polymerases and mutants thereof
|
WO2003030821A2
(en)
*
|
2001-10-05 |
2003-04-17 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20040166490A1
(en)
*
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040126762A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Morris David W. |
Novel compositions and methods in cancer
|
US20040180344A1
(en)
*
|
2003-03-14 |
2004-09-16 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20060040262A1
(en)
*
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
US20040197778A1
(en)
*
|
2002-12-26 |
2004-10-07 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
JP4822490B2
(ja)
*
|
2001-12-07 |
2011-11-24 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
|
US20060275747A1
(en)
*
|
2001-12-07 |
2006-12-07 |
Hardy Stephen F |
Endogenous retrovirus up-regulated in prostate cancer
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
EP2277889B1
(de)
|
2001-12-21 |
2014-07-09 |
Human Genome Sciences, Inc. |
Fusionsproteine von Albumin und Interferon beta
|
IL147414A0
(en)
*
|
2001-12-31 |
2002-08-14 |
Yeda Res & Dev |
Ifnar2 mutants, their production and use
|
JP2005520543A
(ja)
|
2002-03-21 |
2005-07-14 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における新規組成物および方法
|
PL375041A1
(en)
|
2002-04-05 |
2005-11-14 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
US7244565B2
(en)
*
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
CA2480084A1
(en)
*
|
2002-04-10 |
2003-10-16 |
Applied Research Systems Ars Holding N.V. |
Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
|
US7585840B2
(en)
|
2002-04-10 |
2009-09-08 |
Merck Serono S.A. |
Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
|
US7138512B2
(en)
*
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US20030228317A1
(en)
*
|
2002-05-22 |
2003-12-11 |
Prafulla Gokhale |
Gene BRCC-1 and diagnostic and therapeutic uses thereof
|
TWI334785B
(en)
*
|
2002-06-03 |
2010-12-21 |
Serono Lab |
Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
|
EP2302039A1
(de)
*
|
2002-06-13 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Virusähnliche Partikel mit HML-2 gag Polypeptid
|
WO2004007666A2
(en)
*
|
2002-07-12 |
2004-01-22 |
The Regents Of The University Of California |
Steroidogenic factor-1 protein variants and methods of making same
|
CA2492930C
(en)
*
|
2002-07-19 |
2013-01-08 |
Cytos Biotechnology Ag |
Vaccine compositions containing amyloid beta1-6 antigen arrays
|
US20040175359A1
(en)
*
|
2002-11-12 |
2004-09-09 |
Desjarlais John Rudolph |
Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
|
CA2513213C
(en)
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20070218071A1
(en)
*
|
2003-09-15 |
2007-09-20 |
Morris David W |
Novel therapeutic targets in cancer
|
US7767387B2
(en)
*
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US20060210588A1
(en)
*
|
2003-03-26 |
2006-09-21 |
Cytos Biotechnology Ag |
Hiv-peptide-carrier-conjugates
|
US7537767B2
(en)
*
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
ZA200507562B
(en)
*
|
2003-03-26 |
2006-11-29 |
Cytos Biotechnology Ag |
HIV-peptide-carrier-conjugates
|
AU2004227204B2
(en)
|
2003-04-08 |
2010-06-03 |
Yeda Research And Development Co. Ltd |
Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
|
FR2853551B1
(fr)
|
2003-04-09 |
2006-08-04 |
Lab Francais Du Fractionnement |
Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
|
TWI272948B
(en)
|
2003-05-01 |
2007-02-11 |
Ares Trading Sa |
HSA-free stabilized interferon liquid formulations
|
US20070281896A1
(en)
*
|
2003-09-30 |
2007-12-06 |
Morris David W |
Novel compositions and methods in cancer
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
IL158868A0
(en)
*
|
2003-11-13 |
2004-05-12 |
Yeda Res & Dev |
Methods of generating and using stem cells enriched with immature primitive progenitor
|
DE102004008168B4
(de)
*
|
2004-02-19 |
2015-12-10 |
Voxeljet Ag |
Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
|
JP2007526317A
(ja)
*
|
2004-03-01 |
2007-09-13 |
エンゾン ファーマスーティカルズ インコーポレイテッド |
インターフェロン−ベータ・ポリマー結合体
|
IL161673A0
(en)
|
2004-04-29 |
2004-09-27 |
Applied Research Systems |
Compositions and methods for therapy of chemotherapy-induced neuropathy
|
JP2007538048A
(ja)
*
|
2004-05-17 |
2007-12-27 |
アレス トレーディング ソシエテ アノニム |
ヒドロゲル・インターフェロン製剤
|
WO2005117948A1
(en)
|
2004-06-01 |
2005-12-15 |
Ares Trading S.A. |
Method of stabilizing proteins
|
US7731948B2
(en)
|
2004-06-01 |
2010-06-08 |
Ares Trading S.A. |
Stabilized interferon liquid formulations
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
US20080206231A1
(en)
*
|
2004-10-05 |
2008-08-28 |
Oregon Health And Science University |
Compositions and Methods for Treating Disease
|
US20100303760A9
(en)
|
2004-10-27 |
2010-12-02 |
Laboratoires Serono Sa |
Treatment and/or prevention of cancer and/or arthritis
|
GB0424563D0
(en)
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
AU2005304486B2
(en)
*
|
2004-11-10 |
2011-08-11 |
Novartis Vaccines And Diagnostics Inc. |
Deamidated interferon-beta
|
TW200633718A
(en)
*
|
2004-12-16 |
2006-10-01 |
Applied Research Systems |
Treatment of hepatitis c in the asian population
|
EP1865981A2
(de)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
|
EP1871911A2
(de)
|
2005-04-07 |
2008-01-02 |
Chiron Corporation |
Gene in verbindung mit krebs (prlr)
|
US20060242012A1
(en)
*
|
2005-04-22 |
2006-10-26 |
Sumit Agarwal |
Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
|
DK1910421T3
(da)
|
2005-05-18 |
2019-06-24 |
Biofactura Inc |
Sammensætninger og fremgangsmåder til metabolisk selektion af transficerede celler
|
US20070179113A1
(en)
*
|
2005-05-19 |
2007-08-02 |
Schering Aktiengesellachaft |
GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
|
EP1891224A1
(de)
*
|
2005-05-19 |
2008-02-27 |
Bayer Schering Pharma Aktiengesellschaft |
Interferon-beta-gentherapie unter verwendung eines verbesserten, regulierten expressionssystems
|
US20080076729A1
(en)
*
|
2005-05-19 |
2008-03-27 |
Schering Aktiengesellachaft |
Interferon-beta gene therapy using an improved, regulated expression system
|
WO2006122971A2
(en)
*
|
2005-05-19 |
2006-11-23 |
Bayer Schering Pharma Aktiengesellschaft |
Treatment of disease using an improved regulated expression system
|
PT1885753E
(pt)
|
2005-06-03 |
2011-10-06 |
Ares Trading Sa |
Produção de proteína recombinante de ligação a il-18
|
SI1891088T1
(sl)
*
|
2005-06-10 |
2012-02-29 |
Ares Trading Sa |
Postopek za äśiĺ äśenje il-18 vezavnega proteina
|
EP1904092A4
(de)
*
|
2005-07-21 |
2011-08-17 |
Buck Inst For Age Res |
Fibroblasten-wachstumsfaktor-2 fördert neurogenese und nervenschutz und verlängert die lebensdauer bei der huntington-krankheit
|
US20070026463A1
(en)
*
|
2005-07-28 |
2007-02-01 |
Wyeth |
Compositions and methods of mutant Nogo-66 domain proteins
|
CA2617029A1
(en)
*
|
2005-07-29 |
2007-02-08 |
Novartis Ag |
Method and system for in vitro protein folding
|
LT1917276T
(lt)
|
2005-08-26 |
2018-05-25 |
Ares Trading S.A. |
Glikozilinto interferono beta gavimo būdas
|
EP1760092A1
(de)
|
2005-08-26 |
2007-03-07 |
Applied Research Systems ARS Holding N.V. |
System für Screening von Zellen mit hoher Expression von einem interessierenden Protein
|
JP2009507003A
(ja)
*
|
2005-09-01 |
2009-02-19 |
アレス トレーディング ソシエテ アノニム |
視神経炎の治療
|
ES2397289T3
(es)
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
MX2008014971A
(es)
|
2006-05-24 |
2008-12-05 |
Serono Lab |
Regimen de cladribine para tratar esclerosis multiple.
|
EP2193801B1
(de)
|
2006-06-28 |
2012-02-08 |
Yeda Research and Development Co. Ltd. |
Caspase-8 und Wundheilung
|
WO2008005631A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Washington State University |
Genes encoding chavicol/eugenol synthase from the creosote bush larrea tridentata
|
WO2008031051A2
(en)
*
|
2006-09-08 |
2008-03-13 |
United Therapeutics Corporation |
Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
|
CA2673398A1
(en)
*
|
2006-12-19 |
2008-07-03 |
Merrimack Pharmaceuticals, Inc. |
Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
|
WO2008125222A2
(en)
*
|
2007-04-11 |
2008-10-23 |
Bayer Schering Pharma Aktiengesellschaft |
New modulation molecules for an improved regulated expression system
|
WO2008137471A2
(en)
*
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CA2699454C
(en)
*
|
2007-08-27 |
2012-07-24 |
Auxagen, Inc. |
Methods for inhibiting tgf-.beta.
|
EP2207890A4
(de)
*
|
2007-10-05 |
2010-12-15 |
Barofold Inc |
Hochdruckbehandlung aggregierter interferone
|
KR20100099298A
(ko)
*
|
2007-12-20 |
2010-09-10 |
메르크 세로노 에스. 에이. |
Peg인터페론베타 제형
|
IL189408A0
(en)
|
2008-02-10 |
2009-02-11 |
Yeda Res & Dev |
Siva3, its preparation and pharmaceutical compositions containing it
|
JP5822466B2
(ja)
|
2008-03-04 |
2015-11-24 |
ワシントン ステイト ユニバーシティー |
種子油および膜脂質における脂肪酸不飽和化の示差的調節のための組成物および方法
|
EP2288715B1
(de)
|
2008-04-11 |
2014-09-24 |
Merrimack Pharmaceuticals, Inc. |
Humanserumalbumin-linker und konjugate davon
|
WO2009129616A1
(en)
|
2008-04-21 |
2009-10-29 |
Tissue Regeneration Therapeutics, Inc. |
Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
|
US8487006B2
(en)
*
|
2008-09-16 |
2013-07-16 |
Auxagen, Inc. |
Method of enhancing TGF-β signalling
|
WO2010059315A1
(en)
|
2008-11-18 |
2010-05-27 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
US9074005B2
(en)
*
|
2009-01-02 |
2015-07-07 |
Washington State University |
Compositions and methods for modulating plant disease resistance and immunity
|
CN201397956Y
(zh)
*
|
2009-03-23 |
2010-02-03 |
富士康(昆山)电脑接插件有限公司 |
电连接器组件
|
WO2010133967A1
(en)
*
|
2009-05-14 |
2010-11-25 |
University Of Oxford |
Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
|
JP5908397B2
(ja)
|
2009-06-09 |
2016-04-26 |
デフィルス、インコーポレイテッドDefyrus, Inc. |
病原体感染を予防又は治療するためのインターフェロン投与
|
US20110016548A1
(en)
*
|
2009-07-16 |
2011-01-20 |
University Of Southern California |
Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
EP3578205A1
(de)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
|
US20120237975A1
(en)
|
2010-10-01 |
2012-09-20 |
Jason Schrum |
Engineered nucleic acids and methods of use thereof
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
EP2691101A2
(de)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
EP3670536A3
(de)
|
2011-04-01 |
2020-10-07 |
Universität Stuttgart |
Rekombinante polypeptidmitglieder der tnf-liganden-familien mit antikörperbindender domäne und verwendungen dafür
|
ES2563737T3
(es)
|
2011-05-20 |
2016-03-16 |
Ares Trading S.A. |
Composiciones de IFN-beta, métodos de preparación y usos de las mismas
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2850624A1
(en)
|
2011-10-03 |
2013-04-11 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
EP2832856A4
(de)
|
2012-03-29 |
2016-01-27 |
Chugai Pharmaceutical Co Ltd |
Anti-lamp5-antikörper und verwendung davon
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
CA2868398A1
(en)
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9345766B2
(en)
|
2012-08-30 |
2016-05-24 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-ERBB3 agents
|
AU2013344701A1
(en)
*
|
2012-11-15 |
2015-05-28 |
Board Of Supervisors Of Louisiana State Universtity And Agricultural And Mechanical College |
Follicle-stimulating hormone (FSH)/lytic domain fusion constructs and methods of making and using same
|
JP6144355B2
(ja)
|
2012-11-26 |
2017-06-07 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
化学修飾mRNA
|
EP3936137A1
(de)
|
2013-02-07 |
2022-01-12 |
The General Hospital Corporation |
Verfahren zur expansion oder abreicherung von t-regulatorischen zellen
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
US10806773B2
(en)
|
2014-10-09 |
2020-10-20 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable IL-2 dose regimen for treating immune disorders
|
CN108929383B
(zh)
*
|
2017-05-26 |
2021-10-15 |
阿思科力(苏州)生物科技有限公司 |
重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
|
WO2023122716A1
(en)
|
2021-12-22 |
2023-06-29 |
Vanderbilt University |
Next generation transpososomes
|